Keppra is an effective drug, used for the treatment of epilepsy. All patients may buy Keppra in Ireland, who have spasms and epileptic seizures of any severity. If they don’t have a prescription for this anticonvulsant, patients will find it easy to order Keppra online.

The active ingredient of Keppra is Levetiracetam. It has a broad-spectrum antiepileptic action. The action mechanism of Levetiracetam differs from the antiepileptic activity of other anticonvulsants. Keppra eliminates overexcitement of the neural impulses. At that, this anticonvulsant does not affect the basic properties of cells and does not inhibit the normal neurotransmission.

Keppra promotes the inhibition of the increased neurons activity that produce the so called “epileptic foci” in the brain. The anticonvulsant also activates the inhibitory neurotransmitters, such as GABA, which reduce the activity of excitatory neurons in the brain.

After Keppra administration, the maximum Levetiracetam concentration is achieved in 1.3-1.5 hours. The older the patient, the greater the anticonvulsant half-life. It may vary from 6 to 11 hours. In patients with kidney diseases, the drug concentration decreases by approximately two times in 25 hours after Keppra administration.

You may buy this anticonvulsant in conventional pharmacies, as well. Yet, you may place your order without leaving home only if you buy Keppra online. The buyer in Ireland is provided with three forms of the anticonvulsant drug to choose from:

• tablets of 250, 500, 750 and 1000 mg;
• oral solution of 100 mg/ml;
• concentrate for making solution for infusions 100 mg/ml.

The anticonvulsant oral solution may be used to eliminate the symptoms of epilepsy in infants aged 1 month and more. Keppra solution dosing is performed by means of the measuring syringe, supplied with the drug. The dose of Keppra solution for infants ranges from 0.3 to 1,5 ml, twice daily.

Children and adolescents aged 6 months to 17 years should start the anticonvulsant use with 1 ml of Keppra solution twice daily. Every two weeks of the antiepileptic use, the dose of Keppra solution may be increased or decrease by 0.5 ml.

Keppra solution for infusions is administered intravenously. Infusions of this antiepileptic drug may be applied to children over the age of 12 and adults. Patients should begin using this anticonvulsant with the initial Keppra dose of 250 mg, twice a day.

Every 2-4 weeks, the dose of Keppra solution for infusions may be titrated to 250 mg twice a day, but the maximum daily dose should not exceed 3 g. If you buy Keppra for the infusion administration, the duration of the anticonvulsant therapy should not exceed 4 days.

This anticonvulsant tablets are not intended for use in children under 6 years of age, since selecting the dose of pills for this group of patients is impossible. Children aged 6 and more and adults may start the anti-epilepsy treatment with 500 mg of Keppra twice a day. Every 15-30 days, the single Keppra dose may be titrated to 500 mg, but the total daily dose should not exceed 3000 mg.

If you want to stop taking Keppra, the abolition of the drug should be carried out gradually. The process of reducing the antiepileptic drug should be inversely proportional to its increase.

No sufficient data exists about Keppra safety during pregnancy. The largest trial so far was held in Ireland in 2003-2011 on the effects of this anticonvulsant in pregnant women.

Clinical trials have shown that Keppra reduced the severity of epilepsy symptoms only in 18% of women. The frequency of spasms and the number of epileptic seizures has increased in 31% of subjects, treated with this anticonvulsant. Health condition of 51% of women with epilepsy did not change after the use of Keppra.

If the patient requires an urgent emergency treatment of epilepsy, he should buy Keppra. This anticonvulsant has all the characteristics, required for an effective antiepileptic drug:

• it helps improve the patient’s quality of life;
• it eliminates mental disorders that accompany the epilepsy – depression, stress, anxiety, and others;
• it allows controlling the duration and frequency of epileptic seizures.

Keppra administration is not accompanied by any serious side effects. Rarely minor behavioral disorders are possible after the anticonvulsant use.

Keppra mostly doesn’t cause confusion and doesn’t lead to weight gain. This antiepileptic agent contributes not only to the elimination of convulsions and seizures, but also prevents the epilepsy progression.

Advantages of Keppra for eliminating the epilepsy symptoms:

• it does not affect the liver enzymes metabolism;
• Keppra side effects are temporary and mild;
• this anticonvulsant does not violate the cognitive functions;
• it may be used both as a monotherapy and in combination with other antiepileptic drugs;
• it reduces the epilepsy symptoms in those patients, in whom other anticonvulsants have been ineffective;
• virtually does not interact with other drugs.

Keppra was the first Levetiracetam-based anticonvulsant. November 30, 1999 the concentrate for the infusions solution was approved, and nearly ten years later, Keppra tablets went on sale.

The USA became the first country, which started using Keppra to eliminate the epilepsy symptoms. Since 2000, this antiepileptic drug was sold in other countries of the world, including Ireland. Not only conventional, but the online pharmacies, as well, sell Keppra.

Besides Keppra, you may also buy other Levetiracetam-based anticonvulsants in Irish pharmacies. Such drugs are sold under the trademarks Matever and Mevluxa. Both drugs contain Levetiracetam and are the generic versions of Keppra.